Navigation Links
Vical Receives $6.3 Million Payment for Continued Funding of Allovectin-7(R) Phase 3 Trial
Date:6/12/2008

f defined sales levels are achieved. Vical is obligated to pay AnGes tiered royalties based on defined sales levels in the United States, and fixed royalties on rest-of-world sales. Each company will be responsible for obtaining regulatory approvals in any countries where it plans to market Allovectin-7(R).

About Allovectin-7(R)

Allovectin-7(R) is a plasmid/lipid complex containing the DNA sequences encoding HLA-B7 and Beta 2 microglobulin, which together form a Class I Major Histocompatibility Complex, or MHC-I antigen. Injection of Allovectin-7(R) directly into tumors is designed to stimulate an immune response against both local and distant metastatic tumors. Vical conducted a large Phase 2 trial evaluating Allovectin-7(R) immunotherapeutic as a single agent for patients with Stage III or IV metastatic melanoma. Based on advice from clinical experts and detailed guidance received from the FDA in an End-of-Phase 2 meeting, Vical designed the current Phase 3 trial.

Allovectin-7(R) has been granted orphan drug designation for the treatment of invasive and metastatic melanoma by the FDA's Office of Orphan Products Development. Orphan drug designation provides U.S. marketing exclusivity for seven years if marketing approval is received from the FDA, in addition to certain tax benefits for qualifying expenses.

About Metastatic Melanoma

The American Cancer Society has estimated that more than 62,000 new diagnoses of, and approximately 8,400 deaths from, melanoma will occur in 2008 in the United States. Currently, there are no consistently effective therapies for advanced cases of metastatic melanoma where the cancer has spread to other parts of the body. The toxicity associated with FDA-approved treatments such as dacarbazine or interleukin-2 is often significant, resulting in serious or life-threatening side effects in many of the patients treated. Patients with metastatic melanoma often are treated off-label with drugs such as temozo
'/>"/>

SOURCE Vical Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Ending Cervical Cancer Featured at Summit; QIAGEN CEO Issues a Call to Global Women Leaders
2. Promise of Vicals CMV Vaccine Noted by Independent Experts
3. Study Finds QIAGENs HPV Test Offers Greater Long-term Protection From Cervical Disease Than the Pap
4. Nventa Announces Additional Positive Immunological Data From HspE7 Phase 1 Cervical Dysplasia Trial
5. Globus Medical Completes Enrollment Of SECURE(R)-C Cervical Artificial Disc Clinical Trial
6. Nventa Completes Safety Evaluation on Final Cohort in HspE7 Phase 1 Cervical Dysplasia Trial
7. Vical Promotes Melanoma Awareness Month With Allovectin-7(R) Video Report
8. Vical Receives NIH Grant for an Immunotherapeutic Herpes DNA Vaccine; Herpes Experts at University of Washington and University of Texas to Conduct Preclinical Development
9. Gen-Probe Begins U.S. Clinical Study of Molecular Test for Human Papillomavirus, Which Causes Cervical Cancer
10. Nventa Announces Positive Interim Immunological Data From HspE7 Phase 1 Cervical Dysplasia Trial
11. Nventa Enrolls and Initiates Dosing of Final Cohort in HspE7 Phase 1 Cervical Dysplasia Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... LAS VEGAS , July 30, 2014  DigiPath, ... provider that is expanding into the cannabis testing and ... development in its business and affairs not previously disclosed ... for the recent unusual market action. "We ... securities over the last three trading days," said ...
(Date:7/30/2014)... , July 30, 2014 /PRNewswire-iReach/ -- This ... Global and Chinese Heparin sodium (CAS 9041-08-1) & ... the basic information of Heparin sodium (CAS 9041-08-1) ... and manufacturing technology. The report then explores global ... 9041-08-1) & calcium (CAS 37270-89-6) listing their product ...
(Date:7/30/2014)... , July 30, 2014  PDL BioPharma, Inc. ... company management will participate in the Jefferies 2014 Boston ... , Massachusetts. The conference will occur on August 6, 2014 ... BioPharma, Inc. PDL BioPharma manages a portfolio ... Queen et al. antibody humanization patents and license agreements ...
Breaking Medicine Technology:DigiPath No New Corporate Developments 2Heparin Sodium & Calcium Industry for Global and Chinese Markets Forecast to 2019 2Heparin Sodium & Calcium Industry for Global and Chinese Markets Forecast to 2019 3Heparin Sodium & Calcium Industry for Global and Chinese Markets Forecast to 2019 4Heparin Sodium & Calcium Industry for Global and Chinese Markets Forecast to 2019 5PDL BioPharma to Participate in Jefferies 2014 Boston Healthcare Summit 2
(Date:7/30/2014)... York, NY (PRWEB) July 30, 2014 ... substantially during the five years to 2014. Following a ... thanks to beneficial demographic trends, the expansion of private ... result, IBISWorld estimates that Hearing Aid Clinics industry ... 3.4% to $2.7 billion during the five years to ...
(Date:7/30/2014)... 2014 The global market for hearing ... 2020, growing at an estimated CAGR of 3.2% from ... Grand View Research, Inc. Growing global base of geriatric ... to serve this market as a primary growth driver. ... hearing aid technology and patient awareness levels are expected ...
(Date:7/30/2014)... who have the most common genetic mutation linked to ... overweight or obese people who do not have the ... the Endocrine Society,s Journal of Clinical Endocrinology & ... of adults are obese. Obesity typically results from a ... activity and genetics. In particular, consumption of appetizing foods ...
(Date:7/30/2014)... an Ohio teen who died of a caffeine overdose ... well-tolerated and mass-consumed substance. To help prevent serious health ... scientists are reporting progress toward a rapid, at-home test ... most beverages and even breast milk. Their report appears ... . , Mani Subramanian and colleagues note that caffeine,s ...
(Date:7/30/2014)... McKinney, Texas (PRWEB) July 30, 2014 ... surgical hospital, is proud to announce the launch of ... throat (ENT), and general surgery. The doctors working in ... the needs of infants, children, and adolescents. Dr. Timothy ... Kapadia, Dr. Chad McDuffie, Dr. Neelesh Mehendale, and Dr. ...
Breaking Medicine News(10 mins):Health News:Hearing Aid Clinics in the US Industry Market Research Report Now Available from IBISWorld 2Health News:Hearing Aid Clinics in the US Industry Market Research Report Now Available from IBISWorld 3Health News:Hearing Aids Market Analysis by Product (Behind-The-Ear Aids, In-The-Ear Aids, CIC, IIC), by Technology (Analog, Digital) Expected to Reach USD 5,440.5 Million by 2020 2Health News:Hearing Aids Market Analysis by Product (Behind-The-Ear Aids, In-The-Ear Aids, CIC, IIC), by Technology (Analog, Digital) Expected to Reach USD 5,440.5 Million by 2020 3Health News:Hearing Aids Market Analysis by Product (Behind-The-Ear Aids, In-The-Ear Aids, CIC, IIC), by Technology (Analog, Digital) Expected to Reach USD 5,440.5 Million by 2020 4Health News:Hearing Aids Market Analysis by Product (Behind-The-Ear Aids, In-The-Ear Aids, CIC, IIC), by Technology (Analog, Digital) Expected to Reach USD 5,440.5 Million by 2020 5Health News:Brain response to appetizing food cues varies among obese people 2Health News:Victory Medical Center Craig Ranch Debuts Pediatric Care Unit 2Health News:Victory Medical Center Craig Ranch Debuts Pediatric Care Unit 3
... children with the most common form of childhood cancer ... the cancer cells survive their best efforts and the most ... scientists led by researchers at the University of California, San ... a protein that leukemia cells use to stay alive. Targeting ...
... May 18 (HealthDay News) -- Women who smoke during pregnancy ... a DNA change, a new study suggests. The change, ... researchers argue that the altered genes, which can be passed ... more likely than others to develop certain diseases, such as ...
... antigen) level over several years which had been seen ... recently come under fire as a screening test because it ... A new study, however, shows nearly 70 percent of ... were eventually diagnosed with prostate cancer, according to research from ...
... Minn. -- Mayo Clinic has developed a ... for Lynch syndrome ( http://www.mayoclinic.com/health/lynch-syndrome/DS00669 ), a ... particularly for colorectal cancer. An estimated 3 ... to Lynch syndrome. At least 80 percent ...
... products can be high in harmful saturated fat but not ... of thousands of adults in Costa Rica found that their ... their risk of a heart attack. "Things like milk ... community health graduate student at Brown University and the lead ...
... Jefferson and an international team of collaborators have discovered ... women will respond to anti-estrogen therapy. The research ... Journal of Clinical Oncology . Anti-estrogen drugs, most notably ... breast cancer. However, as many as a third of ...
Cached Medicine News:Health News:UCSF team discovers key to fighting drug-resistant leukemia 2Health News:UCSF team discovers key to fighting drug-resistant leukemia 3Health News:When Pregnant Mom Smokes, Baby's DNA May Change 2Health News:When rising PSA means prostate cancer is in patient's future 2Health News:New Mayo Clinic test targets Lynch syndrome, a risk factor for colon cancer 2Health News:Dairy consumption does not elevate heart-attack risk, study suggests 2Health News:Marker identifies breast cancer patients likely to respond to tamoxifen 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: